Louise Rodino-Klapac

Insider Reports History

Entity
Individual
Location
215 First Street, Ste 415, Cambridge, MA
Signature
/s/ Ryan Brown as Attorney-in-Fact for Louise Rodino-Klapac
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Louise Rodino-Klapac:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Sarepta Therapeutics, Inc. Head of R&D, CSO Common Stock 67.6K $6.96M $102.89 Nov 18, 2024 Direct
Sarepta Therapeutics, Inc. Head of R&D, CSO Performance Stock Units 0 $0 $163.23 Jun 21, 2024 Direct
Sarepta Therapeutics, Inc. Head of R&D, CSO Stock Option (right to buy) 12.5K Mar 1, 2024 Direct

Insider Reports Filed by Louise Rodino-Klapac

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SRPT Sarepta Therapeutics, Inc. Nov 18, 2024 1 -$469K 4 Nov 20, 2024 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Jun 21, 2024 5 -$359K 4 Jun 25, 2024 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 7, 2024 2 -$174K 4 Mar 11, 2024 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 4, 2024 1 -$217K 4 Mar 6, 2024 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 1, 2024 3 -$98.2K 4 Mar 5, 2024 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Nov 17, 2023 1 -$374K 4 Nov 20, 2023 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 8, 2023 1 -$140K 4 Mar 10, 2023 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 6, 2023 3 -$178K 4 Mar 8, 2023 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 1, 2023 1 -$77K 4 Mar 3, 2023 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Nov 17, 2022 1 -$457K 4 Nov 21, 2022 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 4, 2022 3 -$96.3K 4 Mar 8, 2022 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Mar 1, 2022 1 -$42.9K 4 Mar 1, 2022 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Nov 24, 2021 1 $300K 4 Nov 29, 2021 Head of R&D, CSO
SRPT Sarepta Therapeutics, Inc. Nov 16, 2021 1 $0 4 Nov 17, 2021 Chief Scientific Officer